Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MSK-TCR5 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on MSK-TCR5, a putative CD8alpha/beta-armored RAS G12D/HLA-A*11:01-targeted T-cell receptor therapy (Jun 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MSK-TCR5 | MSK TCR5|MSKTCR5 | Limited information is currently available on MSK-TCR5, a putative CD8alpha/beta-armored RAS G12D/HLA-A*11:01-targeted T-cell receptor therapy (Jun 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07638371 | Phase I | MSK-TCR5 | A Study of MSK-TCR5 in People With Solid Tumor Cancers | Recruiting | USA | 0 |